

Bayer



Investor News

Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.co

Bayer and Aventis end negotiations on biologicals joint venture

Leverkusen – Bayer and Aventis have agreed not to pursue their plans to create a joint venture in the field of biological products. It had been intended to combine the Biological Products Division of Bayer HealthCare with the Aventis subsidiary Aventis Behring. Both companies reviewed various possible forms of cooperation. A final agreement on the terms of the transaction could not be reached.

Leverkusen, January 31, 2003
